GENENTECH
About
Who We Are
Genentech (GNE), a member of the Roche group and founder of the biotechnology industry, is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. To solve the world's most complex health challenges, we ask bigger questions that challenge our industry and the boundaries of science to transform society. Our transformational discoveries include the first targeted antibody for cancer and the first medicine...
Updates & Highlights
Weekly Rundown: Genentech's oral breast cancer drug gets priority FDA review
Weekly Rundown: Genentech's oral breast cancer drug gets priority FDA review
Drug Discovery News · about 7 hours ago
How Genentech uses Meridian for media measurement - Think with Google
How Genentech uses Meridian for media measurement - Think with Google
Google Business Profile · about 14 hours ago
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and...
Business Wire · 4 days ago
Recent Openings
View all 5 jobsMachine Learning Engineer/Senior Machine Learning Engineer - Infra
New York, NY, US
Senior Machine Learning Engineer
San Francisco, CA, US
Machine Learning Engineer - Devops
New York, NY
Data Scientist, Computational Toxicology
San Francisco, CA, US
All Jobs
Machine Learning Engineer/Senior Machine Learning Engineer - Infra
New York, NY, US
Senior Machine Learning Engineer
San Francisco, CA, US
Machine Learning Engineer - Devops
New York, NY
Data Scientist, Computational Toxicology
San Francisco, CA, US
Machine Learning Engineer - Infra
South San Francisco, CA
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Generous PTO
Paid time off
Competitive Salary
Market-rate compensation
Remote Work
Work from anywhere flexibility
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Genentech?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentWeekly Rundown: Genentech's oral breast cancer drug gets priority FDA review
Weekly Rundown: Genentech's oral breast cancer drug gets priority FDA review
Drug Discovery News · about 7 hours ago
How Genentech uses Meridian for media measurement - Think with Google
How Genentech uses Meridian for media measurement - Think with Google
Google Business Profile · about 14 hours ago
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
Business Wire · 4 days ago
Genentech to present obesity drug trial data at ADA meeting
Genentech to present obesity drug trial data at ADA meeting
Investing.com · 5 days ago
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Caledonian Record · 5 days ago
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
The Malone Telegram · 5 days ago
Lupus Research Alliance, Genentech fund CAR T-cell studies
Lupus Research Alliance, Genentech fund CAR T-cell studies
Lupus News Today · 8 days ago
Immunic Names Former Genentech Executive Erik Lundgren CEO Ahead of Late-Stage MS Push
Immunic Names Former Genentech Executive Erik Lundgren CEO Ahead of Late-Stage MS Push
citybiz · 9 days ago
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Benzinga · 10 days ago
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Yahoo Finance · 10 days ago
Advancing CAR-T Cell Science in Lupus: Meet the First Recipients of the Lupus Research Alliance–Genentech Fund
Advancing CAR-T Cell Science in Lupus: Meet the First Recipients of the Lupus Research Alliance–Genentech Fund
The Dermatology Digest · 10 days ago
Lupus Research Alliance and Genentech Fund Researchers Translating CAR T Success into Durable Lupus Treatments
Lupus Research Alliance and Genentech Fund Researchers Translating CAR T Success into Durable Lupus Treatments
PR Newswire · 11 days ago
How Genentech Is Shaping Cancer Care: Legacy, Partnerships and Innovation
How Genentech Is Shaping Cancer Care: Legacy, Partnerships and Innovation
Genentech · 15 days ago
Genentech is soliciting research that can be used to blunt pharma reforms in Washington
Genentech is soliciting research that can be used to blunt pharma reforms in Washington
statnews.com · 15 days ago
Genentech Highlights New Breast Cancer and Precision Oncology Data Ahead of ASCO 2026 (RHHBY)
Genentech Highlights New Breast Cancer and Precision Oncology Data Ahead of ASCO 2026 (RHHBY)
Yahoo Finance · 18 days ago
Genentech to present breast cancer data at ASCO meeting By Investing.com
Genentech to present breast cancer data at ASCO meeting By Investing.com
Investing.com Canada · 18 days ago
Genentech to present breast cancer data at ASCO meeting By Investing.com
Genentech to present breast cancer data at ASCO meeting By Investing.com
Investing.com Australia · 18 days ago
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
Business Wire · 18 days ago
New FDA approval for Genentech’s Tecentriq
New FDA approval for Genentech’s Tecentriq
The Pharma Letter · 19 days ago
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
BioSpace · 19 days ago